Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 8:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostatic Hypertrophy Clear all
Withdrawn Phase 4 Interventional

The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder

NCT05393921
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Overactive Bladder
Interventions
Intravesical Botox injection
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Cleveland, Ohio • Lyndhurst, Ohio • Richmond Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 10, 2026, 8:44 AM EDT
Completed Phase 3 Interventional

Clinical Trial in Males With BPH (Enlarged Prostate)

NCT00029822
View directory record Official record
Conditions
Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Interventions
Alfuzosin (SL770499)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older · Male only
Enrollment
1,522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
35
States / cities
Huntsville, Alabama • La Mesa, California • San Bernardino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2008 · Synced Sep 10, 2026, 8:44 AM EDT
Recruiting Not applicable Interventional

Preoperative Pelvic Floor Physical Therapy to Minimize Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate

NCT06179654
View directory record Official record
Conditions
Benign Prostatic Hyperplasia With Outflow Obstruction, Urinary Retention, Lower Urinary Tract Symptoms
Interventions
Preoperative pelvic floor physical therapy
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Sep 10, 2026, 8:44 AM EDT
Active, not recruiting No phase listed Observational

Stone and Laser Therapies Post-Market Study (SALT)

NCT06982235
View directory record Official record
Conditions
Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary, Urinary Tract Procedure
Interventions
Ureteroscope system, Laser system
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Phoenix, Arizona • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 10, 2026, 8:44 AM EDT
Completed Phase 2 Interventional

Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems

NCT00547625
View directory record Official record
Conditions
Prostatic Hyperplasia, Prostate
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2007 · Synced Sep 10, 2026, 8:44 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

ProVIDE II Bridging Study

NCT06236802
View directory record Official record
Conditions
BPH With Symptomatic Lower Urinary Tract Symptoms
Interventions
ProVee device
Device
Lead sponsor
ProVerum Medical
Industry
Eligibility
45 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
7
States / cities
Tampa, Florida • Winter Garden, Florida • Lake Barrington, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 10, 2026, 8:44 AM EDT
Completed Phase 1 Interventional

A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057

NCT02916537
View directory record Official record
Conditions
Prostate Cancer
Interventions
CTT1057, Prostatectomy
Drug · Procedure
Lead sponsor
Cancer Targeted Technology
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 10, 2026, 8:44 AM EDT
Recruiting No phase listed Observational

Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia

NCT07016620
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Transperineal Laser Ablation (TPLA)
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older · Male only
Enrollment
20 participants
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 10, 2026, 8:44 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ejaculatory-Sparing HoLEP vs Standard HoLEP

NCT07631286
View directory record Official record
Conditions
Enlarged Prostate (BPH), Enlarged Prostate With Lower Urinary Tract Symptoms
Interventions
Ejaculatory-sparing (ES-sparing) HoLEP
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 10, 2026, 8:44 AM EDT
Withdrawn Not applicable Interventional

Analysis of Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Using Embosphere Microspheres

NCT02679430
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Prostate Arterial Embolization
Device
Lead sponsor
Antonios Likourezos
Other
Eligibility
35 Years to 99 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 10, 2026, 8:44 AM EDT
Active, not recruiting Not applicable Interventional Results available

Optilume™ BPH Catheter System in Men With Symptomatic BPH

NCT04131907
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Optilume BPH Catheter System, Optilume Sham Device
Device
Lead sponsor
Urotronic Inc.
Industry
Eligibility
50 Years to 80 Years · Male only
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
19
States / cities
Little Rock, Arkansas • Golden, Colorado • Daytona Beach, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 10, 2026, 8:44 AM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin Injection for the Management of BPH

NCT00451191
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
botulinum toxin type A (BoNT/A)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years and older · Male only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
Denver, Colorado • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 10, 2026, 8:44 AM EDT
Completed No phase listed Observational

Questioning Patients About Adverse Medical Events

NCT00187616
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older · Male only
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 10, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers

NCT00848081
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
28
States / cities
Huntsville, Alabama • Anchorage, Alaska • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 10, 2026, 8:44 AM EDT
Completed Not applicable Interventional

Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)

NCT02167919
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Microspheres
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 10, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Results available

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

NCT00224107
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Silodosin, Placebo
Drug · Other
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
50 Years and older · Male only
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
43
States / cities
Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 10, 2026, 8:44 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia

NCT03179228
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Prostate Embolization
Device
Lead sponsor
John D Louie
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 10, 2026, 8:44 AM EDT
Terminated Phase 2 Interventional Results available

Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)

NCT03297398
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Group-1 (15mg, OPK-88004), Group-2 (25 mg,OPK-88004), Placebo
Drug · Other
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
15
States / cities
Anniston, Alabama • Lincoln, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 10, 2026, 8:44 AM EDT
Active, not recruiting No phase listed Observational

Impact of COVID-19 on GU Disease

NCT04761107
View directory record Official record
Conditions
COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years and older
Enrollment
15,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 10, 2026, 8:44 AM EDT
Terminated Phase 1Phase 2 Interventional

Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)

NCT02676544
View directory record Official record
Conditions
Benign Prostatic Hypertrophy, Lower Urinary Tract Symptoms
Interventions
Embosphere microspheres
Device
Lead sponsor
Rhode Island Hospital
Other
Eligibility
50 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 10, 2026, 8:44 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)

NCT01912339
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptom
Interventions
Rezum System, Rigid Cystoscopy
Device · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
50 Years and older · Male only
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
Tucson, Arizona • Denver, Colorado • Aventura, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 10, 2026, 8:44 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT01107392
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
botulinum toxin Type A, Normal saline
Drug
Lead sponsor
Allergan
Industry
Eligibility
45 Years and older · Male only
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Sep 10, 2026, 8:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

NCT00634608
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions
Health Information Prescription
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 10, 2026, 8:44 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)

NCT02637960
View directory record Official record
Conditions
Nocturia
Interventions
Fedovapagon 2 mg, Placebo
Drug
Lead sponsor
Vantia Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
48
States / cities
Anniston, Alabama • Goodyear, Arizona • Lincoln, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 10, 2026, 8:44 AM EDT